Mark Ginski
Corporate Officer/Principal bei VISTAGEN THERAPEUTICS, INC.
Profil
Mark J.
Ginski is the founder of Fells Laboratories LLC, which was founded in 2010.
He is currently the Head-Chemistry, Manufacturing & Controls at Vistagen Therapeutics, Inc. since 2021.
Dr. Ginski has previously worked as a Senior Director at Questcor Pharmaceuticals, Inc., an Associate Director-Preformulation Sciences at Shire Acquisition, Inc., and a Senior Director-Product & Analytical Development at Alba Therapeutics Corp.
from 2006 to 2010.
He has also held the position of Principal at Guilford Pharmaceuticals, Inc. and Vice President-Corticotropin Product Development at ANI Pharmaceuticals, Inc. Dr. Ginski obtained his undergraduate and doctorate degrees from the University of Maryland.
Aktive Positionen von Mark Ginski
Unternehmen | Position | Beginn |
---|---|---|
VISTAGEN THERAPEUTICS, INC. | Corporate Officer/Principal | 01.02.2021 |
Ehemalige bekannte Positionen von Mark Ginski
Unternehmen | Position | Ende |
---|---|---|
Fells Laboratories LLC | Gründer | 01.05.2011 |
Alba Therapeutics Corp.
Alba Therapeutics Corp. Pharmaceuticals: MajorHealth Technology Alba Therapeutics Corporation is a privately held, clinical-stage biopharmaceutical Company focused on the discovery, development and commercialization of pharmaceutical products to treat autoimmune and inflammatory diseases and is based in Baltimore, Maryland. Genetics, environment, aberrant immune response, and barrier dysfunction are all required for autoimmunity. Alba's technology platform is based on modifying disease state epithelial permeability using compounds which impact the regulation of tight junctions in cell barriers throughout the body with potential applications in celiac disease, Crohn's disease, asthma/COPD and acute lung injury. As a development stage company Alba maximizes value creation by leveraging its human capital, partnerships and technology. Since the Company's formation in 2004, the company has entered human clinical trials with its lead product, received Fast Track designation from the FDA (in Celiac Disease), successfully completed three Phase I clinical trials and completed its first Phase II study. Along with $30m raised in its Series A financing, equity and non-equity capital, such as SBIR and ATP grants and venture debt, are being used to develop products, enhance its powerful IP position and build the Company's infrastructure and core competencies | Corporate Officer/Principal | 01.08.2010 |
QUESTCOR PHARMACEUTICALS INC | Corporate Officer/Principal | - |
ANI PHARMACEUTICALS, INC. | Corporate Officer/Principal | - |
Shire Acquisition, Inc.
Shire Acquisition, Inc. Pharmaceuticals: MajorHealth Technology The Group's principal activity is the researching, development and marketing of prescription medicines. The Group operations focuses on three therapeutic areas - central nervous system disorders, gastrointestinal and renal diseases. The Group's marketed products for such disorders include ADDERALL and ADDERALL XR, for attention deficit hyperactivity disorder, REMINYL for Alzheimer's, co-marketed with Johnson and Johnson and CARBATROL. for epilepsy. The Group is also developing a range of treatments for ADHD which may treat children, adolescents and adults extending the use of its current brand as well as researching non-scheduled compounds. The Group operates in the United Kingdom, the United States of America, France, Germany, Italy, Spain, Ireland, Canada, the Netherlands and the Cayman Islands. | Corporate Officer/Principal | - |
Ausbildung von Mark Ginski
University of Maryland | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 2 |
---|---|
ANI PHARMACEUTICALS, INC. | Health Technology |
VISTAGEN THERAPEUTICS, INC. | Health Technology |
Private Unternehmen | 5 |
---|---|
Alba Therapeutics Corp.
Alba Therapeutics Corp. Pharmaceuticals: MajorHealth Technology Alba Therapeutics Corporation is a privately held, clinical-stage biopharmaceutical Company focused on the discovery, development and commercialization of pharmaceutical products to treat autoimmune and inflammatory diseases and is based in Baltimore, Maryland. Genetics, environment, aberrant immune response, and barrier dysfunction are all required for autoimmunity. Alba's technology platform is based on modifying disease state epithelial permeability using compounds which impact the regulation of tight junctions in cell barriers throughout the body with potential applications in celiac disease, Crohn's disease, asthma/COPD and acute lung injury. As a development stage company Alba maximizes value creation by leveraging its human capital, partnerships and technology. Since the Company's formation in 2004, the company has entered human clinical trials with its lead product, received Fast Track designation from the FDA (in Celiac Disease), successfully completed three Phase I clinical trials and completed its first Phase II study. Along with $30m raised in its Series A financing, equity and non-equity capital, such as SBIR and ATP grants and venture debt, are being used to develop products, enhance its powerful IP position and build the Company's infrastructure and core competencies | Health Technology |
Guilford Pharmaceuticals, Inc.
Guilford Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Guilford Pharmaceuticals Inc. is a pharmaceutical company engaged in the research, development and commercialization of proprietary drugs that target the hospital and neurology markets. Presently, Guilford markets two commercial products, GLIADEL(R) Wafer, for the treatment of brain cancer, and AGGRASTAT(R) Injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome (ACS). Guilford's product pipeline includes a novel anesthetic, AQUAVAN(R) Injection, and drugs for treating Parkinson's disease and peripheral nerve injury | Health Technology |
Shire Acquisition, Inc.
Shire Acquisition, Inc. Pharmaceuticals: MajorHealth Technology The Group's principal activity is the researching, development and marketing of prescription medicines. The Group operations focuses on three therapeutic areas - central nervous system disorders, gastrointestinal and renal diseases. The Group's marketed products for such disorders include ADDERALL and ADDERALL XR, for attention deficit hyperactivity disorder, REMINYL for Alzheimer's, co-marketed with Johnson and Johnson and CARBATROL. for epilepsy. The Group is also developing a range of treatments for ADHD which may treat children, adolescents and adults extending the use of its current brand as well as researching non-scheduled compounds. The Group operates in the United Kingdom, the United States of America, France, Germany, Italy, Spain, Ireland, Canada, the Netherlands and the Cayman Islands. | Health Technology |
Questcor Pharmaceuticals, Inc.
Questcor Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Questcor Pharmaceuticals, Inc. was engaged in development, marketing and sale of prescription drugs. It operated as a biopharmaceutical company which focuses on the treatment of patients with serious, difficult-to-treat autoimmune and inflammatory disorders. The company's primary product was H.P. Acthar Gel, an injectable drug for the treatment of proteinuria in the nephrotic syndrome of the idiopathic type, or NS, the treatment of acute exacerbations of multiple sclerosis, or MS, in adults, the treatment of infantile spasms, or IS, in infants and children under two years of age, and the treatment of certain rheumatology related conditions, including the treatment of the rare and closely related neuromuscular disorders dermatomyositis and polymyositis. Questcor Pharmaceuticals was founded in September 1992 and was headquartered in Anaheim, CA. | Health Technology |
Fells Laboratories LLC |